La cadena de opciones muestra datos clave de las opciones de acciones de  a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para ..

 (TFFP) Bolsa, Cadena de Opciones

TFF Pharmaceuticals

TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.

TFF Pharmaceuticals Inc

<p>Deep-pocketed investors have adopted a bullish approach towards Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TTD usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Trade Desk. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 30% bearish. Among these notable options, 16 are puts, totaling $802,286, and 4 are calls, amounting to $156,510.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $110.0 to $170.0 for Trade Desk during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Trade Desk options trades today is 493.67 with a total volume of 5,958.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Trade Desk's big money trades within a strike price range of $110.0 to $170.0 over the last 30 days.</p>
<h3>Trade Desk 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734968728_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.0</td>
<td>$7.8</td>
<td>$7.8</td>
<td>$120.00</td>
<td>$155.2K</td>
<td align="right">55</td>
<td align="right">0</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$5.2</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$120.00</td>
<td>$67.5K</td>
<td align="right">99</td>
<td align="right">150</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.35</td>
<td>$4.05</td>
<td>$4.35</td>
<td>$110.00</td>
<td>$65.2K</td>
<td align="right">59</td>
<td align="right">161</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.6</td>
<td>$8.5</td>
<td>$8.5</td>
<td>$120.00</td>
<td>$63.7K</td>
<td align="right">55</td>
<td align="right">312</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$4.8</td>
<td>$4.6</td>
<td>$4.7</td>
<td>$110.00</td>
<td>$47.0K</td>
<td align="right">59</td>
<td align="right">423</td>
</tr>
</tbody>
</table>
</p>
<h3>About Trade Desk</h3>
<p>The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.</p>
<p>In light of the recent options history for Trade Desk, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Trade Desk Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 528,990, with TTD's price down by -2.3%, positioned at $122.14.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 52 days.</li>
</ul>
<h3>What The Experts Say On Trade Desk</h3>
<p>In the last month, 4 experts released ratings on this stock with an average target price of $139.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $135.<br />
&#x2A; In a cautious move, an analyst from Scotiabank downgraded its rating to Sector Outperform, setting a price target of $133.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on Trade Desk, maintaining a target price of $155.<br />
&#x2A; An analyst from Wedbush downgraded its action to Outperform with a price target of $135. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Trade Desk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

Trade Desk's Options Frenzy: What You Need to Know

<p>Investors with significant funds have taken a bullish position in TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), a development that retail traders should be aware of.</p>
<p>This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in TMDX usually indicates foreknowledge of upcoming events.</p>
<p>Today, Benzinga's options scanner identified 9 options transactions for TransMedics Gr. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 33% being bullish and 33% bearish. Of all the options we discovered, 8 are puts, valued at $933,494, and there was a single call, worth $25,600.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $135.0 for TransMedics Gr, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in TransMedics Gr's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to TransMedics Gr's substantial trades, within a strike price spectrum from $60.0 to $135.0 over the preceding 30 days.</p>
<h3>TransMedics Gr 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734968723_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$78.0</td>
<td>$73.2</td>
<td>$75.0</td>
<td>$135.00</td>
<td>$300.0K</td>
<td align="right">2</td>
<td align="right">40</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$73.9</td>
<td>$73.8</td>
<td>$73.8</td>
<td>$135.00</td>
<td>$244.0K</td>
<td align="right">43</td>
<td align="right">33</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$32.5</td>
<td>$28.9</td>
<td>$28.91</td>
<td>$80.00</td>
<td>$144.5K</td>
<td align="right">141</td>
<td align="right">50</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$47.8</td>
<td>$43.6</td>
<td>$45.56</td>
<td>$100.00</td>
<td>$82.0K</td>
<td align="right">37</td>
<td align="right">18</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$20.0</td>
<td>$18.0</td>
<td>$20.0</td>
<td>$65.00</td>
<td>$80.0K</td>
<td align="right">89</td>
<td align="right">40</td>
</tr>
</tbody>
</table>
</p>
<h3>About TransMedics Gr</h3>
<p>TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.</p>
<h3>Present Market Standing of TransMedics Gr</h3>
<ul>
<li>With a trading volume of 288,303, the price of TMDX is up by 1.87%, reaching $62.85.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 63 days from now.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for TransMedics Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


TMDX

Market Whales and Their Recent Bets on TMDX Options

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Nike</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with NKE, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 13 options trades for Nike.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 46% bullish and 46%, bearish.</p>
<p>Out of all of the options we uncovered, 12 are puts, for a total amount of $626,297, and there was 1 call, for a total amount of $36,670.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $100.0 for Nike during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Nike's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Nike's substantial trades, within a strike price spectrum from $70.0 to $100.0 over the preceding 30 days.</p>
<h3>Nike Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734968717_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$22.15</td>
<td>$21.8</td>
<td>$21.8</td>
<td>$100.00</td>
<td>$183.1K</td>
<td align="right">4</td>
<td align="right">84</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$8.45</td>
<td>$8.25</td>
<td>$8.34</td>
<td>$85.00</td>
<td>$55.8K</td>
<td align="right">477</td>
<td align="right">204</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.45</td>
<td>$8.3</td>
<td>$8.3</td>
<td>$85.00</td>
<td>$55.6K</td>
<td align="right">477</td>
<td align="right">271</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.5</td>
<td>$6.25</td>
<td>$6.25</td>
<td>$82.50</td>
<td>$55.0K</td>
<td align="right">324</td>
<td align="right">176</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$18.25</td>
<td>$17.65</td>
<td>$18.17</td>
<td>$95.00</td>
<td>$50.8K</td>
<td align="right">20</td>
<td align="right">29</td>
</tr>
</tbody>
</table>
</p>
<h3>About Nike</h3>
<p>Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.</p>
<p>Having examined the options trading patterns of Nike, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Nike</h3>
<ul>
<li>Trading volume stands at 3,639,215, with NKE's price down by -0.08%, positioned at $76.88.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 87 days.</li>
</ul>
<h3>Professional Analyst Ratings for Nike</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $77.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Hold rating on Nike with a target price of $75.<br />
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $84.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Nike, targeting a price of $73.<br />
&#x2A; An analyst from Deutsche Bank persists with their Buy rating on Nike, maintaining a target price of $82.<br />
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Nike, which currently sits at a price target of $73. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Nike with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Nike Unusual Options Activity

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Jefferies analyst David Stanton downgraded the rating for <strong>Mesoblast Limited</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) from Buy to Hold. Mesoblast shares closed at $14.63 on Friday. <a href="https://www.benzinga.com/quote/MESO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Sami Corwin downgraded <strong>Applied Therapeutics, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) from Outperform to Market Perform. Applied Therapeutics shares closed at $0.8801 on Friday. <a href="https://www.benzinga.com/quote/APLT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG analyst Thomas Catherwood downgraded the rating for <strong>Innovative Industrial Properties, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) from Buy to Neutral. NCR Atleos shares closed at $73.66 on Friday. <a href="https://www.benzinga.com/quote/IIPR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p>Considering buying MESO stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-1024x590.png" alt="" class="wp-image-704457" style="width:578px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


News

Downgrades

Analyst Ratings

Trading Ideas

APLT

IIPR

MESO

This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

SOUN

SoundHound AI Option Alert: Jan 3 $21 Calls Sweep (21) Near The Ask: 483 @ $2.401 Vs 834 OI; Ref=$20.83

<p>Shares of autonomous driving technology leader <strong>Pony AI Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) <a href="https://www.benzinga.com/24/11/42228142/symbotic-unusual-machines-vci-global-pony-ai-tesla-why-these-5-stocks-are-on-investors-radars-today">debuted on Nasdaq in November</a>.</p>
<p>The Fremont, California-based company has the largest fleet of Level 4 autonomous mobility, offering robotaxi and robotruck services across China, according to Goldman Sachs.</p>
<p><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/635ac86c2048c300015a37cd/allen-chang">Analyst <strong>Allen Chang</strong></a> initiated coverage of Pony AI with a Buy rating and a price target of $19.60.</p>
<p><strong>The </strong><strong>Pony AI</strong><strong> Thesis:</strong> The company is the first to operate completely driverless robotaxis in four tier-1 cities in China, having obtained regulatory permits for providing robotaxi services to the general public, Chang said in the initiation note.</p>
<p><strong>Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a></strong>.</p>
<p>While competition is a concern, it will take time for other companies to develop a vehicle that does not need any safety drivers to offer a better riding experience to passengers versus traditional taxis, the analyst stated. </p>
<p>"Besides, it also takes time to accumulate autonomous driving mileage / track record to earn the operation license from governments," he added.</p>
<p>"Pony AI continues to make progress on robotaxi commercialization, and we expect a revenue CAGR of 27% in 2024-27E on ramp up of its robotaxi fleet operation and start of licenses fee contribution from robotaxi solutions, then a 158% CAGR over 2027-30E with accelerated scale expansion, driving EBITDA and NI to turn positive in 2030E," Chang further wrote.</p>
<p><strong>Price Action:</strong> Shares of Pony AI had risen by 4.48% to $13.75 at the time of publication on Monday.</p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42230178/chinas-robotaxi-firm-looks-to-diversify-supply-chain-as-nasdaq-debut-sees-disappointment-amid-global-competition-with-tesla-waymo-and-amazon">China&#8217;s Robotaxi Firm Pony AI Looks To Diversify Supply Chain After Nasdaq Debut, Growing Competition With Tesla, Waymo, And Amazon</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Analyst Color

Long Ideas

Initiation

Movers

PONY

Pony AI Speeds Past Competitors, Commercializes Fully Driverless Vehicles

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Scotiabank analyst Sung Ji Nam initiated coverage on <strong>Thermo Fisher Scientific Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Sector Perform rating and announced a price target of $605. Thermo Fisher Scientific shares closed at $524.05 on Friday. <a href="https://www.benzinga.com/quote/TMO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Allen Chang initiated coverage on <strong>Pony AI Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) with a Buy rating and announced a price target of $19.6. Pony AI shares closed at $13.16 on Friday. See how other analysts view this stock.</li>
<li>Compass Point analyst Dominick Gabriele initiated coverage on <strong>NCR Atleos Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) with a Buy rating and announced a price target of $57. NCR Atleos shares closed at $32.33 on Friday. <a href="https://www.benzinga.com/quote/NATL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on <strong>Omeros Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy rating and announced a price target of $36. Omeros shares closed at $10.31 on Friday. <a href="https://www.benzinga.com/quote/OMER/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Alliance Global Partners analyst Aaron Grey initiated coverage on <strong>Worksport Ltd.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) with a Buy rating and announced a price target of $2. Worksport shares closed at $0.8465 on Thursday. <a href="https://www.benzinga.com/quote/WKSP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>Considering buying OMER stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png" alt="" class="wp-image-704444" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


NATL

OMER

WKSP

This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

RELI

Reliance Global Shares Resume Trade

Reliance Global Shares Halted On Circuit Breaker To The Upside, Stock Now Up 290.8%

DRCT

Direct Digital Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 183.6%

<p><a href="https://www.theinformation.com/articles/openai-nvidia-and-their-rivals-expand-ai-turf-wars" title="https://www.theinformation.com/articles/openai-nvidia-and-their-rivals-expand-ai-turf-wars">https://www.theinformation.com/articles/openai-nvidia-and-their-rivals-expand-ai-turf-wars</a></p>
<p>&nbsp;</p>
<p>Nvidia Aims To Rival AWS With Cloud Services And Software Business; OpenAI Develops Server Chips And Browser To Reduce Nvidia And Google Dependence; Elon Musk Builds Massive Supercomputing Cluster For Conversational AI; Major Tech Firms Race To Expand AI Hardware And Software Stacks Amid Intensifying Competition And Efforts To Reduce Supplier Reliance</p>


MSFT

NVDA

'OpenAI, Nvidia And Their Rivals Expand AI Turf Wars' - The Information

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Boeing</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BA, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 29 uncommon options trades for Boeing.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 55% bullish and 37%, bearish.</p>
<p>Out of all of the special options we uncovered, 6 are puts, for a total amount of $323,005, and 23 are calls, for a total amount of $880,234.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $140.0 to $200.0 for Boeing over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Boeing's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Boeing's significant trades, within a strike price range of $140.0 to $200.0, over the past month.</p>
<h3>Boeing 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734967838_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$36.5</td>
<td>$30.9</td>
<td>$30.9</td>
<td>$200.00</td>
<td>$154.5K</td>
<td>1.7K</td>
<td align="right">0</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/03/25</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$185.00</td>
<td>$113.9K</td>
<td>1.2K</td>
<td align="right">821</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$10.8</td>
<td>$10.55</td>
<td>$10.55</td>
<td>$170.00</td>
<td>$52.7K</td>
<td>11.1K</td>
<td align="right">85</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$4.3</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$150.00</td>
<td>$50.1K</td>
<td>2.8K</td>
<td align="right">812</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$48.2</td>
<td>$47.7</td>
<td>$48.2</td>
<td>$140.00</td>
<td>$48.2K</td>
<td>103</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About Boeing</h3>
<p>Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and Global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with Lockheed, Northrop, and several other firms to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.</p>
<p>In light of the recent options history for Boeing, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Boeing</h3>
<ul>
<li>With a volume of 1,879,101, the price of BA is down -0.28% at $176.86. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 37 days.</li>
</ul>
<h3>What Analysts Are Saying About Boeing</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $190.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Boeing, which currently sits at a price target of $190. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Boeing with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Check Out What Whales Are Doing With Boeing

Direct Digital Holdings Shares Halted To The Upside; Stock Now Up 143.64%

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>ServiceNow</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NOW, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for ServiceNow.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 21% bullish and 64%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $130,910, and 11 are calls, for a total amount of $1,080,381.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $230.0 to $1140.0 for ServiceNow over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of ServiceNow stands at 47.88, with a total volume reaching 98.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in ServiceNow, situated within the strike price corridor from $230.0 to $1140.0, throughout the last 30 days.</p>
<h3>ServiceNow Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734967832_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$280.6</td>
<td>$272.5</td>
<td>$272.5</td>
<td>$850.00</td>
<td>$545.0K</td>
<td align="right">49</td>
<td align="right">20</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$861.7</td>
<td>$848.5</td>
<td>$855.58</td>
<td>$230.00</td>
<td>$85.5K</td>
<td align="right">12</td>
<td align="right">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$862.1</td>
<td>$855.3</td>
<td>$855.3</td>
<td>$230.00</td>
<td>$85.5K</td>
<td align="right">12</td>
<td align="right">1</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$399.8</td>
<td>$393.8</td>
<td>$397.93</td>
<td>$700.00</td>
<td>$79.5K</td>
<td align="right">11</td>
<td align="right">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$321.8</td>
<td>$315.6</td>
<td>$315.6</td>
<td>$860.00</td>
<td>$63.1K</td>
<td align="right">80</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About ServiceNow</h3>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<p>In light of the recent options history for ServiceNow, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>ServiceNow's Current Market Status</h3>
<ul>
<li>Trading volume stands at 86,368, with NOW's price down by -1.13%, positioned at $1078.87.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 30 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for ServiceNow, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Check Out What Whales Are Doing With NOW

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Exxon Mobil</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with XOM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Exxon Mobil.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 22% bullish and 22%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $141,045, and 5 are calls, for a total amount of $265,371.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $42.5 and $115.0 for Exxon Mobil, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Exxon Mobil's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Exxon Mobil's whale activity within a strike price range from $42.5 to $115.0 in the last 30 days. </p>
<h3>Exxon Mobil Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734967826_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.5</td>
<td>$5.35</td>
<td>$5.5</td>
<td>$105.00</td>
<td>$100.1K</td>
<td>2.6K</td>
<td align="right">186</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$65.25</td>
<td>$61.1</td>
<td>$63.13</td>
<td>$42.50</td>
<td>$63.1K</td>
<td>3</td>
<td align="right">0</td>
</tr>
<tr>
<td>XOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$7.0</td>
<td>$6.9</td>
<td>$6.95</td>
<td>$110.00</td>
<td>$49.3K</td>
<td>16.0K</td>
<td align="right">58</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$8.1</td>
<td>$7.95</td>
<td>$8.02</td>
<td>$100.00</td>
<td>$40.1K</td>
<td>837</td>
<td align="right">50</td>
</tr>
<tr>
<td>XOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$7.05</td>
<td>$6.9</td>
<td>$6.92</td>
<td>$110.00</td>
<td>$34.6K</td>
<td>16.0K</td>
<td align="right">52</td>
</tr>
</tbody>
</table>
</p>
<h3>About Exxon Mobil</h3>
<p>ExxonMobil is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 2.4 million barrels of liquids and 7.7 billion cubic feet of natural gas per day. At the end of 2023, reserves were 16.9 billion barrels of oil equivalent, 66% of which were liquids. The company is one of the world's largest refiners with a total global refining capacity of 4.5 million barrels of oil per day and is one of the world's largest manufacturers of commodity and specialty chemicals.</p>
<p>Following our analysis of the options activities associated with Exxon Mobil, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Exxon Mobil Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,980,999, with XOM's price down by -0.4%, positioned at $105.45.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 39 days.</li>
</ul>
<h3>Expert Opinions on Exxon Mobil</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $123.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $115.<br />
&#x2A; An analyst from RBC Capital persists with their Sector Perform rating on Exxon Mobil, maintaining a target price of $115.<br />
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Exxon Mobil, maintaining a target price of $127.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Exxon Mobil with a target price of $125.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Neutral rating for Exxon Mobil, targeting a price of $134. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Exxon Mobil, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Smart Money Is Betting Big In XOM Options

<p>Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 18.39%. Currently, Imperial Oil has a market capitalization of $32.81 billion. </p>
<p><strong>Buying $1000 In IMO:</strong> If an investor had bought $1000 of IMO stock 5 years ago, it would be worth <strong>$2,314.74</strong> today based on a price of $61.23 for IMO at the time of writing.</p>
<h3>Imperial Oil's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734967823_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

<p>Kevin O&#8217;Leary, the well-known entrepreneur and <a href="https://www.benzinga.com/news/24/12/42559810/people-think-kevin-oleary-is-the-mean-shark-but-he-says-im-not-mean-i-just-tell-the-truth-to-keep-families-from-going-broke">investor from Shark Tank</a>, has weighed in on why so many tech CEOs and business leaders are suddenly cozying up to President-elect Donald Trump. During a recent <a href="https://www.youtube.com/watch?v=oML1qbX1_uM">interview</a> on Fox &amp; Friends, O&#8217;Leary said it's not just about Trump's corporate tax policies – the real reason is deregulation.</p>
<p>For context, Trump's policies, such as maintaining the 21% corporate tax rate, undoubtedly appeal to businesses. However, according to O'Leary, the bigger draw is Trump's commitment to cutting federal red tape, making it easier for businesses to grow and operate without constant legal battles and administrative hurdles.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"><strong> The percentage may shock you</strong></a>.</strong></li>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
</ul>
<p>O&#8217;Leary pointed out that federal deregulation under Trump's administration is particularly attractive to companies involved in <a href="https://www.benzinga.com/calendars/m-a">mergers and acquisitions</a>. He noted that Trump will "cool off all these pursuits and change many of the administrative rules that make it harder to get things done."</p>
<p>In simple terms, businesses see Trump as someone who will make it easier for them to operate without worrying about constant interference from regulators. That's a huge selling point for companies looking to expand or innovate.</p>
<h2 class="wp-block-heading">CEOs See Trump as &#8216;The Guy&#8217;</h2>
<p>O&#8217;Leary was direct about why CEOs are eager to meet with Trump. &#8220;They're not stupid,&#8221; he said. &#8220;They're saying, &#8216;Well, I think I'm going to go suck up with him because he's the guy for sure for the next two years.'&#8221;</p>
<p><strong>See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"><strong> </strong><strong>for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</strong></a></strong></p>
<p>This isn't just about tech leaders like Mark Zuckerberg or Jeff Bezos. O&#8217;Leary said leaders from various industries – and even other countries – are lining up to meet with Trump, recognizing his influence and power in shaping business policy.</p>
<h2 class="wp-block-heading">Donations for Trump&#8217;s Inauguration</h2>
<p>Mark Zuckerberg and <a href="https://www.benzinga.com/tech/24/12/42479253/jeff-bezos-amazon-pledges-1-million-to-trumps-inaugural-event-following-in-the-footsteps-of-mark-zuckerberg-and-meta">Jeff Bezos have each contributed $1 million</a> through their companies, Meta Platforms and Amazon. OpenAI CEO Sam Altman is joining them, making a <a href="https://www.benzinga.com/news/management/24/12/42485193/sam-altman-to-donate-1m-to-trumps-inauguration-fund-following-zuckerberg-bezos-eager-to-support">personal donation of $1 million</a>. Perhaps surprisingly, the trading platform Robinhood has donated $2 million.</p>
<p>O&#8217;Leary highlighted that these donations represent a shift in attitude among business leaders. This is about aligning with Trump's vision for the economy and acknowledging his dominance in shaping the future of policy.&nbsp;</p>
<p><strong>Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks"><strong>this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</strong></a></strong></p>
<p>Altman, for instance, has publicly praised Trump's commitment to advancing AI infrastructure, a sentiment echoed by other tech leaders. &#8220;President Donald Trump will lead our country into the age of AI and I am eager to support his efforts to ensure America stays ahead,&#8221; he said.</p>
<p>The President-elect&#8217;s ability to remove regulatory roadblocks has made him an attractive ally for business leaders, regardless of their personal opinions about him.</p>
<h2 class="wp-block-heading">Why Deregulation Can Be Harmful</h2>
<p>While <a href="https://www.benzinga.com/markets/equities/24/11/42383725/trump-administrations-deregulation-efforts-to-lift-energy-oil-and-gas-sectors-ai-frenzy-to-aid-faang-stocks-and-nvidia-says-fintech-insider">deregulation is a win for businesses</a>, it can also result in significant drawbacks. <a href="https://www.imf.org/external/pubs/ft/wp/2013/wp13247.pdf">Reduced oversight</a> often opens the door to harmful practices, such as environmental damage, compromised safety standards and unfair labor practices. It can also mean fewer consumer protections, which could let businesses focus more on profits than on doing what's right for people.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv"><strong>The percentage may shock you</strong></a>.</strong></li>
<li><strong>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>with $1,000 you can invest at just $0.26/share!</strong></a></strong></li>
</ul>


Kevin O'Leary Says Deregulation Is The Real Reason Everybody Is 'Sucking Up To Trump Now,' Not Lower Taxes

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Raymond James analyst Buck Horne upgraded the rating for <strong>Weyerhaeuser Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) from Market Perform to Outperform and announced a $32 price target. Weyerhaeuser shares closed at $27.50 on Friday. <a href="https://www.benzinga.com/quote/WY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgraded the rating for <strong>Aclaris Therapeutics, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintained the price target of $20. Aclaris Therapeutics shares closed at $2.72 on Friday. See how other analysts view this stock.</li>
<li>Piper Sandler analyst Crispin Love upgraded <strong>GCM Grosvenor Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) from Neutral to Overweight and raised the price target from $12.5 to $14. GCM Grosvenor shares closed at $11.75 on Friday. <a href="https://www.benzinga.com/quote/GCMG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Buck Horne upgraded the rating for <strong>PotlatchDeltic Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) from Market Perform to Outperform and announced a $45 price target. PotlatchDeltic shares closed at $38.75 on Friday. <a href="https://www.benzinga.com/quote/PCH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p>Considering buying WY stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png" alt="" class="wp-image-704426" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191.png 1078w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


Upgrades

Price Target

ACRS

GCMG

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

<p><strong>Rumble Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) shares are trading higher Monday after the company announced it entered into a definitive agreement for a $775 million strategic investment from <a href="https://www.benzinga.com/24/12/42634166/rumble-stock-soars-on-775-million-investment-from-tether-what-to-know"><strong>Tether</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>)</a>.</p>
<p><strong>The Details:</strong> Rumble on Friday announced that Tether plans to buy 103.33 million shares of its common stock for $7.50 per share, representing $775 million in gross proceeds. Tether offers the most widely used dollar <a href="https://www.benzinga.com/topic/stablecoins">stablecoin</a> with more than 350 million users. </p>
<p>Rumble plans to use $250 million of the gross proceeds to support growth initiatives, while the remaining funds will be used for a self-tender offer of up to 70 million Rumble shares at the same price as Tether&#8217;s investment.</p>
<p>Rumble CEO <strong>Chris Pavlovski</strong> does not intend to sell more than 10 million shares of common stock in the tender offer. He will retain his controlling stake in the company.</p>
<p>&#8220;I could not be more excited about this collaboration with Tether for a number of reasons. First, many people may not realize the incredibly strong connection between the cryptocurrency and free speech communities, which is rooted in a passion for freedom, transparency, and decentralization,&#8221; Pavlovski said.</p>
<p>&#8220;Second, the immediate commitment of adding $250 million in cash to our balance sheet not only confirms the level of support and commitment to a collaboration between our companies, it also fuels our growth initiatives. And, third, this transaction provides an immediate liquidity event for all of our stockholders who elect to participate in the self tender offer.&#8221;</p>
<p>Rumble&#8217;s existing board and governance structure, including Pavlovski&#8217;s super-majority voting control, will remain unchanged following the closing of the transaction. </p>
<p>Tether will own a minority position in Rumble&#8217;s outstanding common stock, but will not have the right to designate any members of the board. The investment and tender offer are expected to close during the first quarter of 2025. </p>
<p><strong>Related Link: <a href="https://www.benzinga.com/24/12/42647650/palantir-vs-lockheed-a-tech-fueled-showdown-in-the-850-billion-defense-market">Palantir Vs. Lockheed: A Tech-Fueled Showdown In The $850 Billion Defense Market</a></strong></p>
<p><strong>RUM Price Action</strong>: At the time of writing, Rumble shares were up 79.8% at $12.92, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><em>Image: Shutterstock.</em></p>


$USDT

Rumble Stock Is Ripping Higher Monday: What's Going On?

<p>Truist Securities  analyst Joon Lee   maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and lowers the price target from $550 to $460.</p>


VRTX

Truist Securities Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $460

Analyst Justin Walsh of JonesTrading reiterated a Buy rating on TFF Pharmaceuticals (TFFP – Research Report), reducing the price target to $4.00. J...

Buy Rating Affirmed for TFF Pharmaceuticals Amid Strong Clinical Data and Market Potential

TFF Pharmaceuticals, Cleveland Clinic advance influenza vaccine candidates into preclinical testing

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Bottom-picking stocks to buy is one of the most difficult strategies in trading and investing. It is a direct antithesis to the adage, &ldquo;the trend is your friend, until it bends.&rdquo; While not for the faint of heart, bold investors are rewarded with the potential to be rewarded exponentially for the risk they are taking.&nbsp;</p>



<p>Bottom-picking <em>is</em> risky and not something you should always do as an investor. But if you were to do it, here&rsquo;s are a few ways to <em>mitigate</em> those risks.&nbsp;</p>



<p>For example, you can consider quality companies that are otherwise getting battered by sellers and are trading at their 52-week lows. So, today, I&rsquo;ll show you three stocks doing just that. To get my list, I used the filter below:</p>



<ul><li>Stock trades near its 52-week low,</li>



<li>Minimum buy rating from analysts, and</li>



<li>Earnings and revenue growth in the last fiscal year.</li>
</ul><p>Getting buy-rated stocks means analysts see potential recovery in the future. The revenue growth metrics also indicate that the companies are doing relatively well.&nbsp;</p>



<p>This list represents the &ldquo;best three&rdquo; from the screen. I arranged it based on how far each stock is from its 52-week low, from highest to lowest. </p>



<h2>Microvast Holdings (MVST)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst.png"><img width="300" height="222" src="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst-300x222.png" alt="A photo of a Microvast Holdings Inc (MVST) sign outside a building."></a><p>The growing demand for EVs has spotlighted companies like <strong>Microvast Holdings </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/mvst-stock-quote/"><strong>MVST</strong></a>). Microvast specializes in advanced battery technology, wherein it builds and develops battery systems used in utility-scale energy storage systems and electric commercial vehicles.&nbsp;</p>



<p>The company has created various proprietary technologies in the entire battery system. Microvast has a solid footprint globally and sells its products in three main regions: North and South America, EMEA, and Asia Pacific.&nbsp;</p>



<p>Microvast reported a <a href="https://ir.microvast.com/news-releases/news-release-details/microvast-reports-2023-financial-results">49.9% YOY revenue increase in FY&rsquo;23.</a> This excellent performance was primarily due to improvements in the EMEA and Asia Pacific regions. Specifically, EMEA is nearly operating at breakeven. Meanwhile, the business in Asia Pacific is entirely self-funding and profitable. The company is hoping for similar results in the Americas shortly.&nbsp;</p>



<p>In other good news, the company&rsquo;s net loss improved from $158.2 million in 2022 to $106.4 million in 2023. Microvast inches towards complete profitability and analysts have plenty of reasons to rate it as a strong buy. The stock is also trading 53.3% higher than its 52-week low. So, if you&rsquo;re looking for stocks to buy, don&rsquo;t miss out on MVST.</p>



<h2>TFF Pharmaceuticals (TFFP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div><p>Biotech is full of baskets of opportunities waiting to be discovered. New firms race to be first to market. <strong>TFF Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/"><strong>TFFP</strong></a>) is one of these contenders. The company develops the commercialization of patented Thin Film Freezing (TFF) by transforming medicine into a potent dry powder for better results.&nbsp;</p>



<p>TFF has two main drug candidates: Voriconazole Inhalation Powder (TFF VORI) and Tacrolimus Inhalation Powder (TFF TAC). Both products use its patented technology and help lung transplant and pulmonary aspergillosis patients.</p>



<p>A quick glance at TFF Pharma&rsquo;s <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results/">FY&rsquo;23 results</a> reported revenues of $733,871, up from $495,805 in 2023. Harlan Weisman, M.D., the company&rsquo;s CEO, says, &ldquo;Over the last several months, we have made significant progress showing that our Thin Film Freezing technology can be successfully applied.&rdquo; Additionally, TFF TAC is heading to another positive catalyst, as the FDA is expected to provide feedback for its <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-first-quarter-financial-results-and-provides-corporate-update/">Clinical Development Plan in Q2FY&rsquo;24</a>.</p>



<p>Though still operating at a loss, the company managed to minimize net losses to $21.2 million, a noticeable improvement from last year&rsquo;s loss of $31.8 million. The company&rsquo;s excellent prospects and growing financials make a strong case for considering it one of the best bargain stocks to buy.</p>



<p>But if you need something more, you&rsquo;d be happy to know analysts rate TFFP stock as <a href="https://www.nasdaq.com/market-activity/stocks/tffp/analyst-research">a Strong Buy</a>. Additionally, it&rsquo;s trading 25.3% higher from its 52-week low.&nbsp;</p>



<h2>My Size (MYSZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/growthstocks_1600_02-300x169.jpg" alt="Hand of woman watering small plant in pot shaped like growing graph representing growth stocks. Sleeper Growth Stocks"><div>Source: Khakimullin Aleksandr / Shutterstock</div></div><p>Formerly known as Knowledgetree Ventures, <strong>My Size</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mysz-stock-quote/"><strong>MYSZ</strong></a>) is an eCommerce platform that lets users build their online profile and store their personal measurements, which will allow buyers to make purchases to retailers using their data and get the right fit.&nbsp;</p>



<p>While this may sound simple enough, the company uses a <a href="https://mysizeid.com/reports/naiz-fit-a-my-size-inc-company-unveils-groundbreaking-generative-ai-strategies-to-revolutionize-fashion-tech/">groundbreaking generative AI tool</a> that lets users work with specialized language models to help customers receive tailored product reals that suit their needs. In addition, the company&rsquo;s AI provides virtual try-ons that allow customers to mix and match garments and visually show how pairs work together.&nbsp;</p>



<p>My Size reported improvements in FY&rsquo;23. Revenue hit $7 million, up from $4.5 million last year. Meanwhile, the bottom line ended at a $6.38 million loss compared to last year&rsquo;s $8.31 million loss. Unfortunately, <a href="https://investorplace.com/earning-results/2024/04/mysz-stock-earnings-my-size-for-q4-of-2023/">some financial metrics missed estimates</a> for Q4 and the whole year, and the stock has taken a beating ever since.&nbsp;</p>



<p>Still, MYSZ stock is rated as a <a href="https://www.nasdaq.com/market-activity/stocks/mysz/analyst-research">Strong Buy</a>, trading 7.6% higher than its 52-week low. More adventurous investors looking for stocks to buy might see this as an opportunity.&nbsp;</p>



<p><em>On the date of publication, Rick Orford did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com </em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em>Publishing Guidelines</em></a>.</p>
<div><p>Rick Orford is a Wall Street Journal best-selling author, investor, influencer, and mentor. His work has appeared in the most authoritative publications, including Good Morning America, Washington Post, Yahoo Finance, MSN, Business Insider, NBC, FOX, CBS, and ABC News.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/3-52-week-low-losers-ready-to-become-big-time-stock-winners/">3 52-Week-Low Losers Ready to Become Big-Time Stock Winners</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 52-Week-Low Losers Ready to Become Big-Time Stock Winners

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>TFF Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tffp-stock-quote/"><strong>TFFP</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>TFF Pharmaceuticals reported earnings per share of -$1.22. This was above the analyst estimate for EPS of -$1.78.</li><li>The company reported revenue of $650,222.</li><li>This was 766.96% better than the analyst estimate for revenue of $75,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/tffp-stock-earnings-tff-pharmaceuticals-for-q2-of-2024/">TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

TFF Pharmaceuticals GAAP EPS of -$1.22 misses by $0.41, revenue of $0.65M beats by $0.5M

TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment

TFF Pharmaceuticals to wind down operations

TFF Pharmaceuticals ( ($TFFP) ) has provided an announcement. TFF Pharmaceuticals, Inc. is set to dissolve following its board's approval of a liqu...

TFF Pharmaceuticals to Dissolve and Liquidate Assets

16:45 EST TFF Pharmaceuticals (TFFP) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

TFF Pharmaceuticals trading resumes

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

CYCN

EYEN

MVST

MYSZ

TFFP

Health Care

Press Releases

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

General

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Earnings

TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

Comments

(TFFP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL